Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Breast Cancer Research
  • View item
  • Home
  • ICR Divisions
  • Breast Cancer Research
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

PARP inhibitor combination therapy.

Thumbnail
View/Open
Accepted version (550.6Kb)
Date
2016-12
ICR Author
Drean, Amy
Lord, Christopher
Author
Dréan, A
Lord, CJ
Ashworth, A
Type
Journal Article
Metadata
Show full item record
Abstract
In 2014, olaparib (Lynparza) became the first PARP (Poly(ADP-ribose) polymerase) inhibitor to be approved for the treatment of cancer. When used as single agents, PARP inhibitors can selectively target tumour cells with BRCA1 or BRCA2 tumour suppressor gene mutations through synthetic lethality. However, PARP inhibition also shows considerable promise when used together with other therapeutic agents. Here, we summarise both the pre-clinical and clinical evidence for the utility of such combinations and discuss the future prospects and challenges for PARP inhibitor combinatorial therapies.
URI
https://repository.icr.ac.uk/handle/internal/532
DOI
https://doi.org/10.1016/j.critrevonc.2016.10.010
Collections
  • Breast Cancer Research
  • Molecular Pathology
Subject
Animals
Humans
Neoplasms
Poly(ADP-ribose) Polymerases
Drug Combinations
Immunotherapy
Poly(ADP-ribose) Polymerase Inhibitors
Research team
Gene Function
Language
eng
Date accepted
2016-10-26
License start date
2016-12
Citation
Critical reviews in oncology/hematology, 2016, 108 pp. 73 - 85

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.